What is the recommended dosage and duration of caffeine (methylxanthine) therapy for apnea of prematurity in preterm infants?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Caffeine Therapy for Apnea of Prematurity in Preterm Infants

For apnea of prematurity in preterm infants, caffeine citrate should be administered with a loading dose of 20 mg/kg (equivalent to 10 mg/kg caffeine base) followed by a maintenance dose of 5-10 mg/kg/day, with serum levels monitored to maintain concentrations between 5-20 mg/L. 1, 2, 3

Dosage Regimen

Initial Loading Dose

  • Loading dose: 20 mg/kg caffeine citrate IV (equivalent to 10 mg/kg caffeine base) 2, 4
  • Administer intravenously over 30 minutes to minimize side effects

Maintenance Dosing

  • Standard maintenance: 5 mg/kg/day caffeine citrate (2.5 mg/kg/day caffeine base) 2
  • Higher maintenance: 7-10 mg/kg/day caffeine citrate for infants with inadequate response 5
  • Route: Can be administered either intravenously or orally once enteral feeds are established 2
  • Timing: Begin maintenance dose 24 hours after loading dose

Therapeutic Monitoring

  • Target serum concentration: 5-20 mg/L 1
  • First level check: 24-48 hours after loading dose
  • Subsequent monitoring: Only necessary if:
    • Ongoing apnea despite therapy
    • Signs of toxicity
    • Significant hepatic or renal dysfunction
  • Routine monitoring is not required in most infants 24-35 weeks gestational age with normal renal and hepatic function 3

Duration of Therapy

  • Continue therapy until:
    • Infant reaches 34-35 weeks postmenstrual age
    • Infant has been apnea-free for 5-7 days
    • At least 1 week before anticipated discharge

Clinical Efficacy

Caffeine therapy has been shown to:

  • Reduce frequency of apnea episodes by at least 50% within 3-6 days 2
  • Eliminate apnea episodes completely in many infants within 5 days 2
  • Promote successful extubation from mechanical ventilation 3
  • Decrease the incidence of bronchopulmonary dysplasia 3, 5
  • Reduce the risk of extubation failure, particularly in extremely premature infants ≤28 weeks 5

Dosing Considerations

Higher vs. Standard Dosing

  • Higher maintenance doses (7-7.5 mg/kg/day) have shown:
    • Significantly fewer apnea episodes
    • Lower extubation failure rates
    • Reduced incidence of moderate/severe BPD
    • Particularly beneficial in extremely premature infants ≤28 weeks 5
  • However, higher doses are associated with increased side effects 5

Special Populations

  • Extremely premature infants (≤28 weeks) may benefit more from higher maintenance doses (7-7.5 mg/kg/day) 5
  • Early initiation is particularly important in this population

Adverse Effects

Common side effects include:

  • Tachycardia
  • Gastroesophageal reflux
  • Altered sleep and behavior patterns
  • Feeding difficulties 1

More severe but less common effects at higher doses:

  • Jitteriness
  • Irritability
  • Seizures (rare)

Practical Considerations

  • Caffeine citrate is preferred over other methylxanthines (theophylline) due to:
    • Wider therapeutic window
    • Once-daily dosing
    • Fewer side effects 6
  • Caffeine can be administered with intravenous lipid emulsions to reduce peroxidation and limit vitamin loss 1
  • Ensure proper monitoring of vital signs during administration

Pitfalls and Caveats

  • Avoid exceeding serum levels of 20 mg/L to prevent toxicity 1
  • Do not confuse caffeine base with caffeine citrate dosing (caffeine citrate contains 50% caffeine base)
  • Recognize that caffeine has a long half-life in neonates, which may lead to accumulation
  • Be aware that caffeine may increase metabolic rate and caloric requirements
  • Consider that extremely preterm infants may require higher maintenance doses for optimal effect 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Serum caffeine concentrations in preterm neonates.

American journal of perinatology, 2007

Research

Association of Caffeine Daily Dose With Respiratory Outcomes in Preterm Neonates: A Retrospective Cohort Study.

Inquiry : a journal of medical care organization, provision and financing, 2024

Research

Caffeine therapy in preterm infants.

World journal of clinical pediatrics, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.